U.S. Markets open in 1 hr 53 mins

McCormick (MKC) Q2 Earnings & Sales Top the Zacks Consensus

Zacks Equity Research
1 / 2

Why Abbott (ABT) is Poised to Beat Earnings Estimates Again

Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

McCormick & Company, Incorporated MKC came out with second-quarter fiscal 2018 results, wherein adjusted earnings of $1.02 per share came ahead of the Zacks Consensus Estimate of 93 cents and surged 24% year-over-year.

The company still expects adjusted earnings for fiscal 2018 in a range of $4.85-$4.95 per share, reflecting a 14-16% growth year-over-year. This includes an expected positive impact of nearly one percentage point from currency fluctuations.

Earnings Estimate Revision: The Zacks Consensus Estimate for fiscal 2018 has remained unchanged over the past 30 days. Further, if we look at McCormick’s performance in the trailing four quarters (excluding the quarter under review), the company has outperformed the Zacks Consensus Estimate by an average of about 6.1%.

McCormick & Company, Incorporated Price and EPS Surprise
 

McCormick & Company, Incorporated Price and EPS Surprise | McCormick & Company, Incorporated Quote

Revenues: McCormick generated net sales of approximately $1,327.3 million that advanced nearly 19% year over year and also topped the Zacks Consensus Estimate of $1,315 million.

The company expects fiscal 2018 sales to advance nearly 13%-15%, including a two-percentage point positive impact from currency movements.

Zacks Rank: Currently, McCormick carries a Zacks Rank #4 (Sell) which is subject to change following the just released earnings results.

You can see the complete list of today’s Zacks #1 Rank stocks here.

Check back later for our full write up on McCormick’s earnings report!

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
McCormick & Company, Incorporated (MKC) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research